Exelixis Inc Payments to Acquire Debt Securities, Available-for-sale
Exelixis Inc (EXEL) reported Payments to Acquire Debt Securities, Available-for-sale of $887.70 million for the 9-month period ending 2019-09-27, per its 10-Q filed 2019-10-30.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2019-10-30
- Exelixis Inc payments to acquire debt securities, available-for-sale for the quarter ending 2019-09-27 was $369.43M, a 161.47% increase year-over-year.
- Exelixis Inc payments to acquire debt securities, available-for-sale for the quarter ending 2019-06-28 was $278.40M, a 152.00% increase year-over-year.
- Exelixis Inc payments to acquire debt securities, available-for-sale for the quarter ending 2019-03-29 was $239.87M, a 105.83% increase year-over-year.
- Exelixis Inc payments to acquire debt securities, available-for-sale for the quarter ending 2018-12-28 was $189.53M, a 166.78% increase year-over-year.
- Exelixis Inc payments to acquire debt securities, available-for-sale for fiscal 2018 was $557.83M, a 74.82% increase from fiscal 2017.
- Exelixis Inc payments to acquire debt securities, available-for-sale for fiscal 2017 was $319.09M, a 13.57% decline from fiscal 2016.
- Exelixis Inc payments to acquire debt securities, available-for-sale for fiscal 2016 was $369.19M.
- Exelixis Inc payments to acquire debt securities, available-for-sale for fiscal 2016 was $369.19M, a 156.39% increase from fiscal 2016.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2019-09-27 | $369.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $647.83M derived: sum of 2 quarters · filed 2019-10-30 | $887.70M 10-Q · filed 2019-10-30 | $1.08B derived: sum of 4 quarters · filed 2019-10-30 |
| 2019-06-28 | $278.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $518.27M 10-Q · filed 2019-07-31 | $707.80M derived: sum of 3 quarters · filed 2019-07-31 | $849.09M derived: sum of 4 quarters · filed 2019-10-30 |
| 2019-03-29 | $239.87M 10-Q · filed 2019-05-01 | $429.40M derived: sum of 2 quarters · filed 2019-05-01 | $570.69M derived: sum of 3 quarters · filed 2019-10-30 | $681.16M derived: sum of 4 quarters · filed 2019-10-30 |
| 2018-12-28 | $189.53M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $330.82M derived: sum of 2 quarters · filed 2019-10-30 | $441.30M derived: sum of 3 quarters · filed 2019-10-30 | $557.83M 10-K · filed 2019-02-22 |
| 2018-09-28 | $141.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $251.77M derived: sum of 2 quarters · filed 2019-10-30 | $368.30M 10-Q · filed 2019-10-30 | $439.35M derived: sum of 4 quarters · filed 2019-10-30 |
| 2018-06-29 | $110.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $227.01M 10-Q · filed 2019-07-31 | $298.06M derived: sum of 3 quarters · filed 2019-07-31 | $391.29M derived: sum of 4 quarters · filed 2019-07-31 |
| 2018-03-30 | $116.54M 10-Q · filed 2019-05-01 | $187.58M derived: sum of 2 quarters · filed 2019-05-01 | $280.82M derived: sum of 3 quarters · filed 2019-05-01 | |
| 2017-12-29 | $71.04M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $164.28M derived: sum of 2 quarters · filed 2019-02-22 | $319.09M 10-K · filed 2019-02-22 | |
| 2017-09-30 | $93.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $248.05M 10-Q · filed 2017-11-01 | ||
| 2017-09-29 | $93.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $123.55M derived: sum of 2 quarters · filed 2018-11-01 | $248.05M 10-Q · filed 2018-11-01 | $358.72M derived: sum of 4 quarters · filed 2018-11-01 |
| 2017-06-30 | $30.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $154.81M 10-Q · filed 2017-08-02 | $265.49M derived: sum of 3 quarters · filed 2018-05-02 | $324.60M derived: sum of 4 quarters · filed 2018-05-02 |
| 2017-03-31 | $124.49M 10-Q · filed 2017-05-01 | $235.17M derived: sum of 2 quarters · filed 2018-05-02 | $294.29M derived: sum of 3 quarters · filed 2018-05-02 | $444.45M derived: sum of 4 quarters · filed 2018-05-02 |
| 2016-12-31 | $110.68M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $169.79M derived: sum of 2 quarters · filed 2017-11-01 | $319.95M derived: sum of 3 quarters · filed 2017-11-01 | $369.19M 10-K · filed 2017-02-27 |
| 2016-12-30 | $369.19M 10-K · filed 2019-02-22 | |||
| 2016-09-30 | $59.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $209.27M derived: sum of 2 quarters · filed 2017-11-01 | $258.51M 10-Q · filed 2017-11-01 | $282.81M derived: sum of 4 quarters · filed 2017-11-01 |
| 2016-06-30 | $150.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $199.40M 10-Q · filed 2017-08-02 | $223.70M derived: sum of 3 quarters · filed 2017-08-02 | $297.17M derived: sum of 4 quarters · filed 2017-08-02 |
| 2016-03-31 | $49.23M 10-Q · filed 2017-05-01 | $73.53M derived: sum of 2 quarters · filed 2017-05-01 | $147.01M derived: sum of 3 quarters · filed 2017-05-01 | $179.94M derived: sum of 4 quarters · filed 2017-05-01 |
| 2016-01-01 | $143.99M 10-K · filed 2018-02-26 | |||
| 2015-12-31 | $24.30M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $97.78M derived: sum of 2 quarters · filed 2017-02-27 | $130.71M derived: sum of 3 quarters · filed 2017-02-27 | $143.99M 10-K · filed 2017-02-27 |
| 2015-09-30 | $73.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $106.41M derived: sum of 2 quarters · filed 2016-11-03 | $119.69M 10-Q · filed 2016-11-03 | $129.98M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | $32.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $46.22M 10-Q · filed 2016-08-03 | $56.51M derived: sum of 3 quarters · filed 2017-02-27 | |
| 2015-03-31 | $13.28M 10-Q · filed 2016-05-04 | $23.57M derived: sum of 2 quarters · filed 2017-02-27 | ||
| 2014-12-31 | $10.29M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $119.53M 10-K · filed 2017-02-27 | ||
| 2014-09-30 | $109.24M 10-Q · filed 2015-11-10 | |||
| 2013-12-31 | $189.97M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |